Clinical Trial

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

Study acronym: KOMODO-1
Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by any safety signal.
Summary
This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Protocol Amendment History 6 changes
critical Trial terminated 2026-08-05
critical Trial terminated: The study was terminated primarily due to a business decision related to a corporate transaction and was not driven by... 2026-08-05
notable Enrollment reduced: 96 -> 8 participants 2026-08-05
notable Primary completion moved earlier: 2029-02-28 -> 2026-07-28 2026-08-05
minor Completion moved earlier: 2029-05-31 -> 2026-07-28 2026-08-05
notable Trial sites expanded: 5 -> 8 locations 2026-04-14
Trial Details
NCT Number NCT07408089
Lead Sponsor Boundless Bio, Inc.
Conditions Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Enrollment 8 participants
Start Date 2026-02-25
Primary Completion 2026-07-28 (estimated)
Study Completion 2026-07-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-04